Results 101 to 110 of about 886,761 (310)

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

open access: yesMolecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain   +10 more
wiley   +1 more source

People as Changemakers: Community based management for right to education

open access: yes, 2010
This paper addresses the ways in which the community, a primary stakeholder in any education system, can influence the government's initiatives to carry out India's Right to Education Act of 2010.
Kapoor, Richa
core  

Reconstituting the Right to Education [PDF]

open access: yes, 2016
Confronting persistent and widening inequality in educational opportunity, advocates have regarded the right to education as a linchpin for reform. In the forty years since the Supreme Court relegated that right to the domain of state constitutional law,
Weishart, Joshua
core   +1 more source

Citizenship, social and educational rights: Reflections for a pedagogy of human rights Ciudadanía, derechos sociales y educativos: Reflexiones para una pedagogía de los derechos humanos Cidadania, direitos sociais e educacionais: Reflexões sobre educação em direitos humanos

open access: yesEducation Policy Analysis Archives, 2010
This article seeks to address human rights issues from a triple perspective. First, conceptually locating human rights in the context of globalization and making a critique of the liberal conception of human rights.
Eduardo Salvador Vila Merino   +1 more
doaj  

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

open access: yesMolecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu   +10 more
wiley   +1 more source

INTRODUCTION TO THE SPECIAL ISSUE ON THE RIGHT TO EDUCATION

open access: yesOnline Learning, 2019
n the 60 years since the Declaration, changes have swept higher education. The emergence of online education promises that growth in its quality, scale and breadth could insure that education becomes a right.
John R. Bourne   +2 more
doaj   +1 more source

COVID-19 and the right to education in Chile: An opportunity to revisit our social contract. [PDF]

open access: yesInt Rev Educ, 2021
Gelber D   +4 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy